A Phase 1 Study To Evaluate The Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue (Serotype 1, 2, 3, and 4) Plasmid DNA Vaccine (TVDV) Formulated With and Without Vaxfectin.
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Dengue DNA vaccine (Primary) ; Vaxfectin
- Indications Dengue
- Focus Adverse reactions
- Acronyms TVDV
- 21 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 03 Jun 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 03 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.